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Abstract G protein-coupled receptors (GPCRs) in the gut–
brain–pancreatic axis are key players in the postprandial con-
trol of metabolism and food intake. A number of intestinally
located receptors have been implicated in the chemo-detection
of ingested nutrients, and in the pancreatic islets and nervous
system GPCRs play essential roles in the detection of many
hormones and neurotransmitters. Because of the diversity,
cell-specific expression and ‘druggability’ of the GPCR su-
perfamily, these receptors are popular targets for therapeutic
development. This review will outline current and potential
future approaches to develop GPCR agonists for the treatment
of type 2 diabetes. This review summarises a presentation
given at the ‘Novel approaches to treating type 2 diabetes’
symposium at the 2015 annual meeting of the EASD. It is
accompanied by a commentary by the Session Chair,
Michael Nauck (DOI: 10.1007/s00125-015-3823-1).
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Abbreviations
FFAR Free fatty acid receptor
GIP Glucose-dependent insulinotropic polypeptide
GIPR Glucose-dependent insulinotropic polypeptide
receptor
GLP-1 Glucagon-like peptide 1
GLP1R Glucagon-like peptide 1 receptor
GPBAR1 G protein-coupled bile acid receptor
GPCR G protein-coupled receptor
Therapeutics that promote insulin secretion have been a main-
stay of type 2 diabetes treatment for many years. However,
with the rising impact of obesity on the incidence of type 2
diabetes comes an increasing need to target body weight as
well as blood glucose control. Recent years have witnessed an
increasing interest in the gut endocrine system as a source of
novel peptides that regulate energy balance. Glucagon-like
peptide 1 (GLP-1) is a prime example, and has been exploited
pharmacologically for its ability both to trigger glucose-
dependent insulin secretion and to reduce appetite [1]. The
GLP-1 receptor is just one of a range of G protein-coupled
receptors (GPCRs) that enable drugs to target tissues of rele-
vance for type 2 diabetes and obesity, and ligands to other
GPCRs, including free fatty acid receptor 1 (FFAR1, also
known as GPR40), GPR119 and the glucose-dependent
insulinotropic polypeptide (GIP) receptor, have progressed
recently through to clinical trials in humans (for examples,
see [2, 3]).
Why GPCRs?
The GPCR superfamily is comprised of receptors involved
in the detection of a wide range of chemicals, including
nutrients, hormones, neurotransmitters, odorants and tastants
[4]. Their specialised ligand-binding domains are tuned so that
each receptor responds only to a narrow range of chemical
structures. In turn, this provides unique sites for high affinity
and specific drug binding. Restricted expression of individual
GPCRs to a limited range of target tissues is a mechanism
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widely used by the body to enable highly specific inter-organ
crosstalk, with the endocrine system being a prime example.
New GPCR-based drug therapies exploit the cell specificity of
receptor expression to achieve activation of a selected range of
target tissues, including pancreatic beta cells, gut endocrine
cells and neuronal populations involved in the suppression of
appetite (for examples, see [1, 3, 5]). They aim to fool the body
into believing that it has just eaten a meal, thereby enhancing
glucose-dependent insulin secretion and reducing hunger.
GPCRs that have received recent attention in the field of
diabetes therapeutics include the incretin receptors (GLP1R,
GIPR), GPR119, FFAR1 (GPR40), FFAR4 (GPR120) and the
bile acid receptor GPBAR1 (TGR5) (for examples, see [2, 3,
5–7]) (see text box). Activation of these receptors is normally
associated with the postprandial state, as they are variously the
targets for nutrients, bile acids and gut hormones [4].
Although there is a well-recognised GPCR capable of detect-
ing glucose—the sweet taste receptor TAS1R2/3 heterodimer
[8]—non-GPCR mechanisms appear to dominate postprandi-
al glucose-dependent insulin and GLP-1 release, which are
instead achieved through metabolism-dependent closure of
ATP-sensitive potassium (KATP) channels in beta cells or elec-
trogenic sodium-dependent glucose transport in GLP-1-
secreting L cells [9, 10].
TheGLP-1 receptor as an exemplary beta cell GPCR
The GLP-1 receptor GLP1R is probably the best characterised
GPCR to have been harnessed to date for the treatment of
diabetes. It is targeted by injectable GLP-1 mimetics as well
as by raised circulating active GLP-1 concentrations achieved
following dipeptidyl peptidase 4 (DPP4) inhibition, but has
proved a difficult target for developing small molecule ligands
that could be administered in oral formulations [11]. Together
with the receptor for GIP, GLP1R activation underlies the phys-
iological incretin effect, responsible for about 50% of postpran-
dial insulin secretion [12]. The incretin effect relies on the high
expression by pancreatic beta cells of GLP1R and GIPR, acti-
vation of which results in recruitment of Gαs G protein subunits
and elevation of cytoplasmic cAMP concentrations [13].
Activation of GLP1R has the highly favourable property
that it normally only triggers insulin secretion in the context of
a raised blood glucose concentration. Hypoglycaemic side
effects of therapeutic GLP-1mimetics are therefore rare unless
used in combination with sulfonylureas [14]. This is because
cAMP is a poor beta cell secretagogue unless the cytoplasmic
calcium concentration is elevated by a separate signalling
pathway, usually downstream of either glucose-dependent or
sulfonylurea-dependent closure of KATP channels [13]. As
well as stimulating insulin secretion, GLP1R agonists sup-
press glucagon release, slow gastric emptying, reduce appetite
and improve myocardial performance during ischaemia [14,
15]. In rodent and in vitro studies, GLP-1 exhibits proliferative
and anti-apoptotic effects on beta cells that could potentially
be exploited to enhance beta cell mass, but the translatability
of these findings to humans remains uncertain [16]. Some
studies have also suggested effects of GLP-1 on liver
metabolism [17] and memory/cognition [18], although the
tissue localisation of the receptors underlying these effects is
unclear [19]. Identifying the tissue distribution of GLP1R and
providing mechanistic explanations for the wide variety of
Summary of the natural ligands, targets and actions of example GPCRs located in intestinal and pancreatic endocrine
cells
Receptor Natural ligands Target cell types/tissues Effect of GPCR agonism
GLP1R GLP-1, oxyntomodulin Pancreatic beta and delta cells, brain,
vagus nerve
↑ insulin, ↓ glucagon, ↓ gastric
emptying
GIPR GIP Pancreatic alpha, beta and delta cells,
adipose tissue
↑ insulin, ↑ glucagon, ↑ fat
storage
GCGR Glucagon, oxyntomodulin Pancreatic beta cells, liver, adipose
tissue, brain





alpha and beta cells




Long-chain NEFA Enteroendocrine cells, pancreatic beta
cells
↑ GLP-1, ↑ GIP, ↑ insulin
FFAR4
(GPR120)
Long-chain NEFA Enteroendocrine cells, pancreatic delta
cells, grehlin cells




Bile acids Enteroendocrine cells, adipose tissue ↑ GLP-1, ↑ energy expenditure
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effects of GLP-1 will be critical for exploiting this receptor
fully.
GPCRs in the spotlight
The global success of GLP1R-based therapeutics has
highlighted the benefits of targeting the gut–pancreatic axis,
as well as the potential effectiveness of drugs that activate
Gαs-coupled receptors in pancreatic beta cells. Similar to the
action of GLP-1, effects of other GPCR agonists also seem to
exhibit glucose-dependence at the level of the beta cell. For
example, GIP enhances glucose-dependent insulin secretion,
likely because GIPR, like GLP1R, is coupled to cAMP eleva-
tion and requires a concomitant calcium signal before secre-
tion is initiated. GIP-based therapeutics were not developed
alongside GLP-1 in the 1990s because early studies concluded
that the peptide loses effectiveness in the diabetic state, per-
haps secondary to receptor downregulation in the beta cell [7].
There is, however, a growing interest in developing GIPR
ligands in the form of new GLP-1–GIP dual agonist peptides
[20]. This is just one example of a recent trend to develop
peptides or peptide combinations that target two or three dis-
tinct GPCRs, each conferring a distinct metabolic profile. It
has been proposed that this approach can potentially amplify
beneficial metabolic effects whilst reducing the doses, and
hence side effects, of individual peptide components [1]. For
example, the combination of GLP-1 with glucagon, targets
GLP1Rs and glucagon receptors (GCGRs) on the beta cell
(both Gαs-coupled), and in animal studies causes potent
weight loss, perhaps by enhancing energy expenditure (via
GCGR), whilst concomitantly reducing food intake (via
GLP1R) [5].
GPR119 is a Gαs-coupled receptor responsive to the natural
ligands oleoylethanolamide and monooleoylglycerol [21].
A number of small molecule GPR119 agonists have been
developed, aiming to enhance insulin secretion and reduce
appetite by targeting gut endocrine cells alongside pancreatic
beta cells. However, despite good evidence of efficacy in
animal models, GPR119 agonists did not have metabolic
benefits in humans with type 2 diabetes [2]. Why this should
be the case remains unclear, and the possibility exists that the
rodent and human enteroendocrine axes differ substantially in
their use of this receptor. The findings with GPR119 raise
another important question: how much endogenous GLP-1
will need to be secreted in response to L cell-targeted GPCR
ligands in order to trigger a therapeutically relevant metabolic
effect? Establishing the answer to this question is critical. It is
not difficult to argue that the supraphysiological levels of
GLP1R ligand achieved by GLP-1 mimetic therapy, or the
approximately tenfold elevated GLP-1 and peptide YY levels
found after gastric bypass surgery [22], have profound effects
on appetite and metabolism. In comparison, attempts to target
gut endocrine cells have produced relatively modest increases
in plasma GLP-1 concentrations. Developing strategies that
produce more substantially enhanced secretion of GLP-1
would seem an essential ambition.
Interestingly, glucose-dependent stimulation of insulin
secretion is not restricted to Gαs-coupled receptors, and
has also been observed with Gαq-coupled receptors
linked to protein kinase C activation and inositol 1,4,
5-trisphosphate (IP3)-dependent calcium release from in-
tracellular stores. One of the classical Gαq-coupled re-
ceptors linked to insulin secretion is the muscarinic ace-
tylcholine receptor M3, responsible for the vagal stimu-
lation of insulin release in some species [23]. Whereas
M3 receptors are expressed in a wide variety of tissues,
precluding their selection as drug targets for diabetes,
FFAR1 (GPR40) and FFAR4 (GPR120) are Gαq-coupled
long-chain fatty acid receptors that have been a focus
for small molecule development [24]. GPR40 is
expressed in both pancreatic beta cells and gut endo-
crine cells, suggesting that its agonism might enhance
insulin and GLP-1 secretion in type 2 diabetes. One of
the GPR40 agonists to have progressed furthest in develop-
ment, TAK-875, exhibited blood glucose lowering efficacy in
Phase 3 clinical trials, but its clinical development was termi-
nated because of concerns about liver toxicity [3]. Whether
this was a class effect or a compound-specific off-target effect
remains to be fully established, although reports that GPR40 is
not expressed in hepatocytes and that TAK-875 impaired the
function of bile acid-related transporters lends hope to the idea
that structurally unrelated GPR40 ligands might not similarly
target the liver [3, 25]. Indeed, newer GPR40 ligands have
been developed that target different binding sites on the recep-
tor and achieve ‘superagonism’ at the level of GLP-1 secretion
[26].
The development of GPR120 agonists has lagged behind
that of GPR40 ligands. This alternative NEFA receptor is
expressed and functional in gut endocrine cells and linked to
the release of GLP-1 and GIP [27, 28], but recent data suggest
its pancreatic expression is high in somatostatin-producing
delta cells and relatively low in beta cells [29]. Indeed, the
application of flow cytometry techniques, transgenic mouse
models with fluorescently labelled endocrine cell types and
RNA sequencing has enabled the separation and transcrip-
tomic analysis of different murine and human pancreatic islet
cell types, providing molecular explanations for the well-
recognised ability of certain drugs and physiological stimuli
differentially to trigger or inhibit the release of one or more
islet or gut hormones. Interestingly, GPR120 coupling to G
proteins appears to be specific to the cell context: whereas
Gαq-dependent pathways are likely to underlie GPR120-
dependent GLP-1 secretion [27], predominant Gαi coupling
has been found in gastric ghrelin-secreting cells [30] and pan-
creatic delta cells [29].
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It is physiologically and therapeutically relevant to note
that whereas GLP-1 stimulates insulin secretion but sup-
presses glucagon release, GIP results in elevated circulating
levels of both hormones [31, 32]. The suppression of plasma
glucagon is one reason why GLP-1-based therapies are
thought to be particularly effective in type 2 diabetes, although
the mechanism underlying the inhibition of pancreatic alpha
cells remains under debate. One proposed explanation is that a
lower density of GLP1Rs thanGIPRs in alpha cells results in a
relatively modest elevation of cAMP in response to GLP-1
compared with GIP, and that this translates into opposite
effects on glucagon release [33]. In perfused rat pancreas
experiments, both GLP-1 and GIP stimulated insulin release,
whereas GLP-1 decreased but GIP increased glucagon
release, replicating observations made in humans [34]. In
parallel, these studies revealed that both GLP-1 and GIP trig-
gered somatostatin secretion and that the inhibitory effect of
GLP-1 on glucagon release was lost in the presence of somato-
statin receptor inhibitors. The data therefore suggest that one
mechanism by which GLP-1 suppresses glucagon secretion is
via the local release of somatostatin, consistent with the finding
that Glp1r is expressed in only ∼10% of alpha cells [19].
Exploring new GPCR targets for diabetes
and obesity
Based on the extensive clinical experience of enhancing
GLP1R activation for the treatment of diabetes, it can
reasonably be concluded that highly desirable properties
for new GPCR agonists would include: Gαs- or Gαq-
coupled receptor activity on pancreatic beta and delta
cells, low receptor activity on alpha cells, high activity
on GLP-1-producing L cells and direct central nervous
system effects to reduce food intake. Transcriptomic and
functional comparisons between the different endocrine
cell types, together with the recent identification of the
human GPCR-ome [35 ] may ye t y i e l d some
new GPCRs that fulfil these criteria which could be
developed as candidate drug targets. However, many
questions remain unanswered, perhaps the most notable
of which is how to achieve substantial stimulation of
postprandial gut endocrine secretion. Gut hormones are
released physiologically by a variety of components of
ingested food, which already recruit a host of GPCRs in
enteroendocrine cells. If enteroendocrine cell GPCRs are
already maximally activated by ingested food, then we
will need to be somewhat cleverer if we are going to
enhance gut hormone secretion further. A strategy that
sensitises endocrine cells along the length of the gut to
the arrival of food in the upper gastrointestinal tract
might be effective, but how to achieve this ambition
remains an enigma.
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